Home / Themes / Rare Diseases '25: Gene Therapy & Genetic Med
Rare Diseases '25: Gene Therapy & Genetic Med
Last updated
Theme thesis · 2/5 sections · Tickers 0 with notes · 7 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsGene therapy is entering a commercial breakthrough phase for rare diseases, backed by regulatory flexibility, a Medicare out-of-pocket revolution, and maturing
Thesis
Gene therapy is entering a commercial breakthrough phase for rare diseases, backed by regulatory flexibility, a Medicare out-of-pocket revolution, and maturing delivery science. Investors are positioned to benefit from both binary upside and increased durability of rare disease franchises.
Bull case
$2K Medicare Cap Is Game-Changer for Six-Figure, One-Time Therapies: W/ therapies priced at $500K–$3M, many gene therapy patients (esp w/ early-onset diseases) faced prohibitive cost-share. The new IRA cap dramatically expands the eligible patient pool, accelerating rev ramps for comm/launch names like KRYS, QURE, SRPT.
FDA Is Actively Streamlining Gene Therapy Approval Process: 12/24 FDA draft guidance confirms CBER-CDER alignment and expanded use of surrogate endpoints (e.g., protein expression, biomarker reduction), improving PoS and speed for RD with severe phenotypes. This supports devs NTLA, SRRK, RARE.
Manufacturing & Delivery Bottlenecks Are Being Solved in Real Time: The leaders in this cohort have shown meaningful scale-up improvements in AAV delivery, lipid nanoparticle tech (NTLA), and topical/intramuscular platforms (KRYS, SRPT) — reducing historical friction around durability, dosing, and immune responses.
Bear case
Commercial Uptake for Gene Therapies Disappoints Despite Policy Tailwinds: If providers remain hesitant or insurers delay reimbursement, real-world uptake may lag, raising questions about total addressable market (TAM) and ROI.
Safety or Durability Events Spark FDA Reversal: Gene therapy setbacks (e.g., insertional mutagenesis, immunogenicity) could lead to re-imposition of clinical hold risk or more conservative FDA stances on Accelerated Approval.
Cost-Sharing Burden Shifts to Manufacturers: The IRA's 20% manufacturer rebate for new launches could increase pricing pressure over time — particularly if CMS includes more gene therapies in price negotiations starting in 2026+.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Gene Therapy Approvals + Accelerated Approvals for Genetic Rare Diseases | Ongoing | Continued uptick = favorable policy execution; slowdown = potential regulatory friction | Google_Sheets |
| Real-World Uptake of Gene Therapies (Rx Trends + Claims Data) | Monthly | Uptake of approved gene therapies (e.g., Vyjuvek, Elevidys) = validation of pricing + access assumptions | Google_Sheets |
| Manufacturing Milestones and COGS Trends | Quarterly | Lower cost of goods or scale-up wins = positive operating leverage; delays = capex drag, margin risk | Google_Sheets |
Constituents
- KRYST3· no notes yet
- NTLAT3· no notes yet
- QURET3· no notes yet
- RARET3· no notes yet
- SLNOT3· no notes yet
- SRPTT3· no notes yet
- SRRKT3· no notes yet